Precision radiation plus immunotherapy shows promise for bile duct cancer

NCT ID NCT07291947

Recruiting now Disease control Sponsor: Wang Xin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for advanced bile duct cancer, combining a precise type of radiation (PULSAR) with immunotherapy drugs and chemotherapy. The goal is to see if this combination is safe and effective. The trial is recruiting 60 adults aged 18-75 with confirmed bile duct cancer that has spread.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iparomlimab and Tuvonralimab Injection (QL1706) combined with chemotherapy and PULSAR radiation therapy
What this could lead to: If successful, this could offer a new treatment option for advanced bile duct cancer by combining precise radiation with immune-boosting drugs.
What could go wrong: This is an early-phase trial with only 60 participants, so results may not apply to all patients. The combination therapy may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLANGIOCARCINOMA

Contacts and locations

Locations

West China Hospital
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.